




The relative strengths and weaknesses of Crescent Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Crescent Biopharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 82% points. The greatest weakness of Crescent Biopharma INC is the variable Net Income, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 269%, being 25% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	50,715
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,881
Liabilities, Non-Current	0
Other Assets	853
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	75
Property and Equipment	242
Research and Development	28,391
Selling, General and Administrative Expense	19,087

Output Variable	Value in 1000 USD
Assets	51,811
Liabilities	8,881
Expenses	47,478
Revenues	75
Stockholders Equity	42,930
Net Income	-47,403
Comprehensive Net Income	-47,403
BaseVar	54,122
ECR before Limited Liability	152%
Economic Capital Ratio	269%